SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
ESMO Breast Cancer 2024 – Olema digs deep to declare victory
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
